Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CRHBP | P24387 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30096583 | 1.00 | PARP1 (0.44) | PARP1DRD2DRD3HTR2AHTR2C | |
| SCHEMBL29549652 | 0.82 | PARP1 (0.36) | PARP1DRD2DRD3HTR3ANPC1 | |
| SCHEMBL19751544 | 0.73 | PIK3CA (0.37) | PIK3CAPIK3CB | |
| SCHEMBL18614540 | 0.73 | PIK3CA (0.38) | PIK3CAHTTLMNAPIK3CB | |
| SCHEMBL15828690 | 0.70 | MAT2A (0.34) | PIK3CAPIK3CB | |
| SCHEMBL2038155 | 0.68 | PARP1 (0.41) | PARP1HTR2AHTR2CHTR3AMCL1 | |
| SCHEMBL30023373 | 0.68 | PARP1 (0.41) | PARP1HTR2AHTR2CHTR3AMCL1 | |
| SCHEMBL979553 | 0.67 | HTR2A (0.40) | HTR2AHTR2CMCL1ITGB2ICAM1 | |
| SCHEMBL405139 | 0.67 | DRD2 (0.48) | PARP1DRD2DRD3HTR2AHTR2C | |
| SCHEMBL406231 | 0.66 | DRD2 (0.47) | PARP1DRD2DRD3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194406-A1 | TRICYCLIC HETEROCYCLES FOR USE AS BET PROTEIN INHIBITORS | Incyte Holdings Corporation (US) | 2017-07-26 | — | — | EP | claimed |
| WO-2016044130-A1 | TRICYCLIC HETEROCYCLES FOR USE AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2016-03-24 | — | — | WO | claimed |
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| US-20220213086-A1 | AZOLE COMPOUNDS AS IRAK INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. | 2022-07-07 | — | — | US | disclosed |
| US-20220169645-A1 | COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | Eternity Bioscience Inc. | 2022-06-02 | — | — | US | disclosed |
| US-11332492-B2 | CD73 inhibitors and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-05-17 | — | — | US | disclosed |
| US-20220135539-A1 | BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | Eternity Bioscience Inc. | 2022-05-05 | — | — | US | disclosed |
| US-20220009909-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. | 2022-01-13 | — | — | US | disclosed |
| US-20220009910-A1 | TYROSINE KINASE 2 INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. | 2022-01-13 | — | — | US | disclosed |
| US-20220002267-A1 | TYROSINE KINASE 2 INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. | 2022-01-06 | — | — | US | disclosed |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| US-20210253621-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| EP-2970282-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | Incyte Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014143768-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002267-A1 | TYROSINE KINASE 2 INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | TYK2, ABL1, PTK2B | PARP1 1819/4885DRD2 4858/4885DRD3 4877/4885 |
| US-20210253621-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | ENTPD5, ENTPD1, NT5E | PARP1 319/4885DRD2 4713/4885DRD3 4745/4885 |
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | STING1, CGAS, MAVS | PARP1 444/4885DRD2 4636/4885DRD3 4462/4885 |
| US-20220213086-A1 | AZOLE COMPOUNDS AS IRAK INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | IRAK2, IRAK4, IRAK3 | PARP1 952/4885DRD2 4884/4885DRD3 4879/4885 |
| US-11332492-B2 | CD73 inhibitors and therapeutic uses thereof | ENTPD5, ENTPD1, NT5E | PARP1 319/4885DRD2 4713/4885DRD3 4745/4885 |
| US-20220135539-A1 | BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | BRAF, NRAS, RAF1 | PARP1 1945/4885DRD2 4867/4885DRD3 4854/4885 |
| US-20220009910-A1 | TYROSINE KINASE 2 INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | TYK2, PTK2B, LCK | PARP1 1722/4885DRD2 4840/4885DRD3 4861/4885 |
| US-20220169645-A1 | COMPOUNDS AS BRUTON TYROSINE KINASE INHIBITORS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | BTK, LYN, LCK | PARP1 1789/4885DRD2 4868/4885DRD3 4858/4885 |
| US-20220009909-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | ADAMTS5, ADAMTS4, ADAMTS1 | PARP1 1422/4885DRD2 4884/4885DRD3 4881/4885 |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | STING1, CGAS, MAVS | PARP1 444/4885DRD2 4636/4885DRD3 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.